Showing 741-750 of 6902 results for "".
Clinical Neuroinflammatory Mimics of Multiple Sclerosis
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/clinical-neuroinflammatory-mimics-of-multiple-sclerosis/54599/NMOSD, MOGAD, and MS have overlapping clinical presentations but are distinct inflammatory CNS diseases, each with their own established diagnostic criteria.Investigating Inebilizumab for Generalized Myasthenia Gravis: Results from MINT
https://reachmd.com/programs/neurofrontiers/investigating-inebilizumab-for-generalized-myasthenia-gravis-results-from-mint/35495/Recently published in The New England Journal of Medicine, the phase 3 Myasthenia Gravis Inebilizumab Trial (MINT) underscores the potential of inebilizumab as a therapeutic option for patients with generalized myasthenia gravis (gMG). This is based on the efficacy findings that inebilizumab signifiElevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
https://reachmd.com/programs/conversations-in-cv-risk-assessment/elevating-cv-risk-assessment-why-uacr-deserves-a-seat-at-the-table/36245/Could kidney-related markers like urine albumin-to-creatinine ratio (uACR) reshape how clinicians approach cardiovascular risk discussions? To explore this question, Dr. Brian McDonough sits down with Dr. Javier Morales, Associate Professor of Medicine at the Donald and Barbara Zucker School of MediDecision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases
https://reachmd.com/programs/cme/decision-in-context-a-practical-framework-for-sequencing-systemic-and-cns-therapies-in-brain-metastases/54765/Apply clinical evidence on intracranial activity of systemic therapies to guide treatment sequencing and multidisciplinary care in brain metastases.Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
https://reachmd.com/programs/project-oncology/early-onset-endometrial-cancer-bridging-the-gap-between-age-and-outcome/35510/Explore how a novel predictive model outperforms TNM and SEER staging in guiding early-onset endometrial cancer management and improving individualized survival predictions.New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
https://reachmd.com/programs/clinicians-roundtable/vkd-maternal-obesity-neonatal-vitamin-k/39657/Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/Are you ready and willing to change your treatment approach for your patients with TNBC? Our experts break down the guidelines to get you on track.New Treatment Approaches for Historically Inoperable Pancreatic Cancers
https://reachmd.com/programs/advanced-treatments-innovations-mayo-clinic/new-treatment-approaches-historically-inoperable-pancreatic-cancers/11143/Dive into the groundbreaking study that’s turning the traditional approach to “inoperable” pancreatic cancer on its head.Latest TROP2 ADC Approval for HR+ HER2- Metastatic Breast Cancer
https://reachmd.com/programs/medical-industry-feature/latest-trop2-adc-approval-for-hr-her2-metastatic-breast-cancer/29175/There’s been recent progress with antibody-drug conjugates (ADCs) for HER2-negative breast cancers,1-3 and most recently, patients with metastatic HR+ HER2- breast cancer. The phase III TROPION-Breast01 study examined the efficacy and safety of datopotamab deruxtecan-dInk (Dato-DXd) compared to inveRamping Up to Manage COVID-19 Patients
https://reachmd.com/programs/covid-19-frontlines/ramping-up-to-manage-covid-19-patients/11527/Every COVID-19 care team has unique issues based on their situation, which is why collaboration and communication is key.